Reliability of a simple non-invasive method for the evaluation of 5- HT2 receptors using [18F]-setoperone PET imaging

Nuclear Medicine Communications

Volumn 18, Issue 5, 1997, Pages 395-399

  Kapur, Shitij ^a,b   Jones, Corey ^a   DaSilva, Jean ^a   Wilson, Alan ^a   Houle, Sylvain ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SEROTONIN 2 RECEPTOR; SETOPERONE; SETOPERONE F 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING; RELIABILITY;

EID: 0031007725     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006231-199705000-00002     Document Type: Article

References (18)

1. Leonard BE. Serotonin receptors - where are they going? (review). Int Clin Psychopharmacol 1994; 9(suppl. 1): 7-17.
2. 2 receptor imaging in vivo: Why do we need them? Eur J Nucl Med 1996; 23: 867-870.
3. Seeman P. Receptor tables: Drug dissociation constants for neuroreceptors and transporters, Vol. 2. Toronto: SZ Research, 1993.
4. 18F]setoperone: A new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol 1988; 147: 73-82.
5. 2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem 1990; 54: 1744-1754.
6. 18F]-setoperone. J Lab Comp Radiopharm 1988; 25: 403-414.
7. Blin J, Crouzel C. Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography. J Neurochem 1992; 58: 2303-2310.
8. Evans AC, Thompson CJ, Marrett S et al. Performance evaluation of the PC-2048: A new 15-slice encoded-crystal PET scanner for neurological studies. IEEE Trans Med Imag 1991; 10: 90-98.
9. Petit-Taboue MC, Landeau B, Osmont A et al. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. J Nucl Med 1996; 37: 95-104.
10. Mazoyer B. Investigation of the dopamine system with positron emission tomography: General issues in modelling. In: Baron J, Comar D, Farde L, Martinot J, Mazoyer B, eds. Brain dopaminergic systems: Imaging with positron emission tomography. Dordrecht: Kluwer Academic, 1991: 64-83.
11. Mintun MA, Raichle ME, Kilbourn MR et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-227.
12. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psych Bull 1979; 86: 420-428.
13. Wong DF, Wagner HN Jr, Dannals RF et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393-1396.
14. Sadzot B, Lemaire C, Maquet P et al. Serotonin 5HT(2) receptor imaging in the human brain using positron emission tomography and a new radioligand, [F-18]altanserin: Results in young normal controls. J Cereb Blood Flow Metab 1995; 15: 787-797.
15. Volkow ND, Fowler JS, Wang J-J et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993; 23: 609-613.
16. 11C-raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Human Psychopharmacol 1992; 7: 157-165.
17. 2-dopamine receptors. Biol Psychiatry 1996; 39: 515.
18. Cohen J. The t test for means. In: Cohen J, ed. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988: 19-74.